The involvement of major signaling pathways in metastasis of colorectal cancer and the therapeutic application of their inhibitors.

IF 2.8 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2025-08-01 Epub Date: 2025-07-10 DOI:10.1080/14737140.2025.2519860

Mehran Molavand, Majid Montazer, Somayyeh Ghareghomi, Bahman Yousefi, Maryam Majidinia

{"title":"The involvement of major signaling pathways in metastasis of colorectal cancer and the therapeutic application of their inhibitors.","authors":"Mehran Molavand, Majid Montazer, Somayyeh Ghareghomi, Bahman Yousefi, Maryam Majidinia","doi":"10.1080/14737140.2025.2519860","DOIUrl":null,"url":null,"abstract":"Introduction: Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality, with metastasis being a key determinant of poor prognosis. Understanding the molecular mechanisms governing CRC metastasis is crucial for developing targeted therapeutic strategies. This review focuses on the involvement of major signaling pathways in CRC metastasis and their potential as therapeutic targets.Areas covered: This review discusses the role of key signaling pathways, including PI3K/Akt, MAPK/ERK, Notch, Wnt/β-catenin, Hippo, and Hedgehog in CRC metastasis. We conducted a literature review using databases such as PubMed and Web of Science to identify recent studies on the molecular mechanisms of metastasis and the efficacy of pathway-targeted therapies.Expert opinion: The complexity of CRC metastasis underscores the need for multi-targeted therapeutic approaches. While significant advances have been made in pathway-specific inhibitors, clinical translation remains challenging. Further research is needed to refine biomarker-driven treatments and develop novel combination therapies to improve patient outcomes.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"915-938"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2519860","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality, with metastasis being a key determinant of poor prognosis. Understanding the molecular mechanisms governing CRC metastasis is crucial for developing targeted therapeutic strategies. This review focuses on the involvement of major signaling pathways in CRC metastasis and their potential as therapeutic targets.

Areas covered: This review discusses the role of key signaling pathways, including PI3K/Akt, MAPK/ERK, Notch, Wnt/β-catenin, Hippo, and Hedgehog in CRC metastasis. We conducted a literature review using databases such as PubMed and Web of Science to identify recent studies on the molecular mechanisms of metastasis and the efficacy of pathway-targeted therapies.

Expert opinion: The complexity of CRC metastasis underscores the need for multi-targeted therapeutic approaches. While significant advances have been made in pathway-specific inhibitors, clinical translation remains challenging. Further research is needed to refine biomarker-driven treatments and develop novel combination therapies to improve patient outcomes.

查看原文本刊更多论文

结直肠癌转移中主要信号通路的参与及其抑制剂的治疗应用。

结直肠癌（CRC）仍然是癌症相关死亡的主要原因之一，转移是预后不良的关键决定因素。了解控制结直肠癌转移的分子机制对于制定靶向治疗策略至关重要。本文综述了主要信号通路在结直肠癌转移中的作用及其作为治疗靶点的潜力。涵盖领域：本文综述了关键信号通路，包括PI3K/Akt、MAPK/ERK、Notch、Wnt/β-catenin、Hippo和Hedgehog在结直肠癌转移中的作用。我们使用PubMed和Web of Science等数据库进行了文献综述，以确定最近关于转移的分子机制和途径靶向治疗效果的研究。专家意见：结直肠癌转移的复杂性强调了多靶点治疗方法的必要性。虽然在途径特异性抑制剂方面取得了重大进展，但临床转化仍然具有挑战性。需要进一步的研究来完善生物标志物驱动的治疗方法，并开发新的联合治疗方法来改善患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.